报 告 人:Dr. Hanping Feng

Associate Professor

Department of Microbial Pathogenesis

Department of Microbiology and Immunology

University of Maryland

650 W. Baltimore Street

Baltimore, MD 21201

TEL: 410-706-7917

Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it.

Web URL: http://www.dental.umaryland.edu/dentaldepts/micropath/feng_lab_faculty_bio.html

报告时间: 2013年1月2日上午10:00-11：00

报告地点: 生物药学楼3-403

联系人：樊柳荫

报告人基本信息：

Dr. Hanping Feng is an Immunologist with strength in the areas of Cell Biology and Infectious Diseases. He is an Associate Professor in both Department of Microbial Pathogenesis and Department of Microbiology and Immunology at the University of Maryland Baltimore. He is holding multiple NIH awards and leading a research team over ten people to study host immune response to Clostridium difficile infection and to design immune-based interventions against these diseases.

Dr. Feng came to the United States in 1999 to start his PhD study. During the last 13-years, he has made the following significant achievements:

1) Established novel theory of immunogenicity of apoptotic tumor cells (4 Blood papers in roll) during the PhD study (Blood is the 1st Journal in Hematology, Impact Factor 10.55)

2) First to identify the INF-beta production in unconventional dendritic cells during the postdoctoral study (Journal of Immunology paper)

3) NIH career development award in 2007

4) Two NIH R01 awards in 2010 (total award > $5.5 million)

5) Distinguished Plenary Awards at DDW congress in 2011 (Gastroenterology 2011)

6) NIH P20 grant Reviewer at Study Section (ZGM1 TWD-A)

7) For the first time generated bioactive recombinant Clostridium difficile holotoxins A and B, which is now distributing >30 labs worldwide

8) For the first time identified toxemia in Clostridium difficile infection

9) Established the first Clostridium difficile infection relapse animal model

10) Developed a novel vaccine against Clostridium difficile infection which is ready to move to clinical trial

11) Identified anti-tumor activity of Clostridium difficile toxins

12) Published > 30 papers in last 10 years, including in Nature Med, Gastroenterology, Blood, JID, JI, IAI etc)

13) Awarded 3 patents (or pending) within last 3 years.